{"id":"av-gbm-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3939716","moleculeType":"Small molecule","molecularWeight":"415.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug is manufactured by isolating dendritic cells from the patient, loading them with glioblastoma-associated antigens, and reinfusing them to prime T-cell responses against the tumor. This personalized immunotherapy approach aims to generate durable anti-tumor immunity in glioblastoma patients, typically used in combination with standard-of-care treatments.","oneSentence":"AV-GBM-1 is an autologous dendritic cell vaccine designed to stimulate the patient's immune system to recognize and attack glioblastoma tumor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:01.318Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma (newly diagnosed or recurrent)"}]},"trialDetails":[{"nctId":"NCT05100641","phase":"PHASE3","title":"AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM","status":"NOT_YET_RECRUITING","sponsor":"Aivita Biomedical, Inc.","startDate":"2024-01","conditions":"Primary Glioblastoma","enrollment":672},{"nctId":"NCT02033616","phase":"PHASE2","title":"Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas","status":"UNKNOWN","sponsor":"Aivita Biomedical, Inc.","startDate":"2017-11-18","conditions":"Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma, Fallopian Tube Carcinoma","enrollment":99},{"nctId":"NCT03400917","phase":"PHASE2","title":"Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma","status":"UNKNOWN","sponsor":"Aivita Biomedical, Inc.","startDate":"2018-06-20","conditions":"Newly Diagnosed Glioblastoma","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AV-GBM-1","genericName":"AV-GBM-1","companyName":"Aivita Biomedical, Inc.","companyId":"aivita-biomedical-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"AV-GBM-1 is an autologous dendritic cell vaccine designed to stimulate the patient's immune system to recognize and attack glioblastoma tumor cells. Used for Glioblastoma (newly diagnosed or recurrent).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}